S'abonner

Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study - 31/12/13

Doi : 10.1016/S1470-2045(13)70546-1 
Roberta De Angelis, MSc a, , Milena Sant, MD b, Michel P Coleman, ProfBM BCh d, Silvia Francisci, PhD a, Paolo Baili, MSc b, Daniela Pierannunzio, PhD a, Annalisa Trama, MD c, Otto Visser, MD e, Hermann Brenner, ProfMD f, Eva Ardanaz, MD g, Magdalena Bielska-Lasota, ProfMD h, Gerda Engholm, MSc i, Alice Nennecke, MD j, Sabine Siesling, PhD e, Franco Berrino, MD c, Riccardo Capocaccia, MSc a

the EUROCARE-5 Working Group

  Members of the EUROCARE-5 Working Group are listed in the Supplementary Material

a Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy 
b Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy 
c Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy 
d Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK 
e Comprehensive Cancer Center the Netherlands, Utrecht, Netherlands 
f Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany 
g Registro de Cáncer de Navarra, Instituto de Salud Pública de Navarra, Pamplona, Spain 
h National Institute of Public Health—National Institute of Hygiene, Warsaw, Poland 
i Danish Cancer Society, Copenhagen, Denmark 
j Hamburg Cancer Registry, Hamburg, Germany 

* Correspondence to: Roberta De Angelis, Centro Nazionale di Epidemiologia Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, I-00161, Rome, Italy

Summary

Background

Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE—the largest cooperative study of population-based cancer survival in Europe—has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries.

Methods

In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were applied to all datasets. For patients diagnosed 2000–07, we calculated 5-year relative survival for 46 cancers weighted by age and country. We also calculated country-specific and age-specific survival for ten common cancers, together with survival differences between time periods (for 1999–2001, 2002–04, and 2005–07).

Findings

5-year relative survival generally increased steadily over time for all European regions. The largest increases from 1999–2001 to 2005–07 were for prostate cancer (73·4% [95% CI 72·9–73·9] vs 81·7% [81·3–82·1]), non-Hodgkin lymphoma (53·8% [53·3–54·4] vs 60·4% [60·0–60·9]), and rectal cancer (52·1% [51·6–52·6] vs 57·6% [57·1–58·1]). Survival in eastern Europe was generally low and below the European mean, particularly for cancers with good or intermediate prognosis. Survival was highest for northern, central, and southern Europe. Survival in the UK and Ireland was intermediate for rectal cancer, breast cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovarian, colon, and lung cancers. Survival for lung cancer in the UK and Ireland was much lower than for other regions for all periods, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation. Survival usually decreased with age, although to different degrees depending on region and cancer type.

Interpretation

The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe. Likely explanations of differences in survival between countries include: differences in stage at diagnosis and accessibility to good care, different diagnostic intensity and screening approaches, and differences in cancer biology. Variations in socioeconomic, lifestyle, and general health between populations might also have a role. Further studies are needed to fully interpret these findings and how to remedy disparities.

Funding

Italian Ministry of Health, European Commission, Compagnia di San Paolo Foundation, Cariplo Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2014  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 15 - N° 1

P. 23-34 - janvier 2014 Retour au numéro
Article précédent Article précédent
  • Times Like These: men with breast cancer
  • Francesca Towey
| Article suivant Article suivant
  • Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
  • Gemma Gatta, Laura Botta, Silvia Rossi, Tiiu Aareleid, Magdalena Bielska-Lasota, Jacqueline Clavel, Nadya Dimitrova, Zsuzsanna Jakab, Peter Kaatsch, Brigitte Lacour, Sandra Mallone, Rafael Marcos-Gragera, Pamela Minicozzi, Maria-José Sánchez-Pérez, Milena Sant, Mariano Santaquilani, Charles Stiller, Andrea Tavilla, Annalisa Trama, Otto Visser, Rafael Peris-Bonet, the EUROCARE Working Group †

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.